Full Text (PDF)
Case Report

Digoxin Therapy for Fetal Supraventricular Tachycardia Diagnosed at 29 Weeks Gestation

Nitisha Lath* , Savita Bansal** , Pratibha Singh***

Author Information

Licence:




Indian Journal of Obstetrics and Gynecology 4(1):p 57-61, January - April 2016. | DOI: DOI: https://dx.doi.org/10.21088/ijog.2321.1636.4116.11

How Cite This Article:


Timeline

Received : N/A         Accepted : N/A          Published : N/A

Abstract

Fetal Supraventricular tachycardia (SVT), though rare, is the most commonly encountered clinically significant tachycardia in the fetus. When  SVT is  sustained, congestive heart failure and fetal hydrops may ensue, due to both systolic and diastolic dysfunction.  Sonographic diagnosis is usually incidental during the second or third trimester. Treatment goals are cardioversion to sinus rhythm and reversal of cardiac dysfunction [1]. Digoxin has been successfully used to treat fetal SVT, when therapy with digoxin fails alternative therapies may be used with equivocal results [2]. There is no clear consensus regarding the best drug-treatment regimens for fetal SVT. Digoxin has been recommended as first-line therapy in cases of SVT with cardiac failure, but recent evidence suggests that the transplacental passage may be impaired in the presence of hydrops [3]. Other agents such as flecainide and sotalol have been tried as first-line agents but with adverse events [4].

 We here describe a case of fetal supraventricular tachycardia without hydrops diagnosed antenatally at 29 weeks of gestationand managed with oral digoxin.


References

No records found.


About this article


Cite this article


Licence:




Received Accepted Published
N/A N/A N/A

DOI: DOI: https://dx.doi.org/10.21088/ijog.2321.1636.4116.11

Keywords


Article Level Metrics

Last Updated

Wednesday 17 June 2026, 23:14:14 (IST)


1422

Accesses

2
152
00

Citations


NA
NA
NA

Download citation


Article Keywords


Keyword Highlighting

Highlight selected keywords in the article text.


Timeline


Received N/A
Accepted N/A
Published N/A

licence



Access this article



Share